Drug
AGN-190584
AGN-190584 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_3
1
25%
Ph phase_2
2
50%
Ph phase_4
1
25%
Phase Distribution
0
Early Stage
2
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Completed2
Withdrawn2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 22 (50.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
Trials by Status
completed250%
withdrawn250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_3
A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age
NCT04837482
withdrawnphase_4
Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses
NCT05624320
withdrawnphase_2
Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia
NCT05393089
completedphase_2
Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia
NCT02197806
Clinical Trials (4)
Showing 4 of 4 trials
NCT04837482Phase 3
A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age
NCT05624320Phase 4
Using AGN-190584 in Subjects Utilizing Single -Use Daily, Contact Lenses
NCT05393089Phase 2
Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia
NCT02197806Phase 2
Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4